GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Ghrelin Inhibition Restores Glucose Homeostasis in Hepatocyte Nuclear Factor-1α (MODY3)-Deficient Mice.
Brial. François F; Lussier. Carine R CR; Belleville. Karine K; Sarret. Philippe P; Boudreau. François F
Key Findings
- HNF1α‑deficient mice have elevated ghrelin production in the gut and bloodstream.
- High ghrelin levels are linked to impaired insulin secretion and hyperglycemia in these mice.
- Pharmacological blockade of ghrelin (using a ghrelin antagonist) restores normal glucose homeostasis in the mouse model.
Practical Outcomes
- For biohackers, the study suggests that excess ghrelin activity may hinder blood‑sugar regulation, especially in people with genetic or metabolic insulin‑secretion issues. While the work is in mice, it hints that using ghrelin‑blocking agents could be beneficial for glucose control, whereas ghrelin‑stimulating peptides like GHRP‑6 might need to be used cautiously in insulin‑resistant individuals.
Summary
In mice lacking the HNF1α gene (a model of a rare form of diabetes), the hormone ghrelin was found to be too high, which messed up insulin release. Blocking ghrelin's action with an antagonist fixed the blood‑sugar problems, showing that too much ghrelin can worsen glucose control.
Abstract
Hepatocyte nuclear factor-1α (HNF1α) is a transcription factor expressed in tissues of endoderm origin. Mutations in HNF1A are associated with maturity-onset diabetes of the young 3 (MODY3). Mice deficient for Hnf1α are hyperglycemic, with their pancreatic β-cells being defective in glucose-sensing insulin secretion. The specific mechanisms involved in this defect are unclear. Gut hormones control glucose homeostasis. Our objective was to explore whether changes in these hormones play a role in glucose homeostasis in the absence of Hnf1α. An increase in ghrelin gene transcript and a decrease in glucose-dependent insulinotropic polypeptide (GIP) gene transcripts were observed in the gut of Hnf1α-null mice. These changes correlated with an increase of ghrelin and a decrease of GIP-labeled cells. Ghrelin serological levels were significantly induced in Hnf1α-null mice. Paradoxically, GIP levels were also induced in these mice. Treatment of Hnf1α-null mice with a ghrelin antagonist led to a recovery of the diabetic symptoms. We conclude that upregulation of ghrelin in the absence of Hnf1α impairs insulin secretion and can be reversed by pharmacological inhibition of ghrelin/GHS-R interaction. These observations open up on future strategies to counteract ghrelin action in a program that could become beneficial in controlling non-insulin-dependent diabetes.
Study Information
pubmed
2015
2015-05-15T00:00:00.000Z
10.2337/db15-0124
23
27